Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

RSS icon
he U.S. Food and Drug Administration (FDA) granted market clearance ion September 2022 for the Edwards Lifesciences Corp. Pascal Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER). It is indicated for the treatment of patients with degenerative mitral regurgitation (DMR).

FDA clears Edwards Pascal device for transcatheter mitral valve repair

This is the second FDA-cleared transcatheter repair device for the mitral valve. Data from pivotal trial comparing Pascal vs. MitraClip will be presented at TCT 2022.

A structural heart Presentation during the TVT 2022 conference. #TCT #TCT22 #TCT2022

TCT 2022 late-breaking clinical presentations announced

The Cardiovascular Research Foundation (CRF) announced the 32 late-breaking studies being presented at the Transcatheter Cardiovascular Therapeutics 2022 annual meeting at in Boston, Sept. 16-19.

Interview with Rebecca T. Hahn, MD, Professor of Medicine at Columbia University Irving Medical Center, Chief Scientific Officer of the Echo Core Lab at the Cardiovascular Research Foundation and Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center. She discusses some of the trends of growing use of interventional echocardiographic guidance in transcatheter structural heart procedures, the growing number of tricuspid valve procedures, and use of 3D ICE.

VIDEO: Trends in structural heart procedural imaging - a discussion with Rebecca Hahn

Rebecca T. Hahn, MD, Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center, discusses some of the trends in the growing use of interventional echocardiographic guidance in transcatheter structural heart procedures.

Juan F. Granada, MD, president and chief executive officer of the Cardiovascular Research Foundation (CRF) and assistant professor of medicine at Columbia University College of Physicians and Surgeons, explains some of the highlights of the upcoming 2022 Transcatheter Cardiovascular Therapies (TCT) conference sponsored by CRF. #TCT #TCT2022

VIDEO: Previewing TCT 2022 in Boston with Juan Granada

Juan F. Granada, MD, president and chief executive officer of the Cardiovascular Research Foundation, previewed TCT 2022 for us, detailing what attendees can expect to see at the big show in Boston. 

The Medtronic CoreValve Evolut and the Edwards Lifesciences Sapien 3 TAVR valves.

TAVR's success has changed how cardiologists and surgeons view aortic valve replacement

The standard-of-care thinking on TAVR has shifted from getting a valve implanted and managing immediate complications to looking decades down the road and considering the patient's long-term health. 

idea light bulb innovation

What to expect at the TCT MedTech Innovation Forum during TCT 2022

The all-day summit, a collaboration between CRF and Fogarty Innovation, will focus on advances in healthcare technologies and patient care.

Three systems for left ventricular pacing during TAVR, modified TAVR valve delivery wire, the Opsens Savvy wire, and the Teleflex Wattson wire.

VIDEO: Use of temporary left ventricular pacing during TAVR procedures

Philippe Genereux, MD, medical director of the structural heart disease program at Morristown Medical Center, discusses the various options used for temporary pacing of the heart during transcatheter aortic valve replacement (TAVR) procedures.

Thumbnail

American Heart Association and Cardiovascular Research Foundation announce a new annual meeting collaboration

“Harnessing the strengths of our two pioneering organizations with extensive experience in translating the latest scientific breakthroughs into practical therapies is crucial," says AHA CEO Nancy Brown.

Displaying 65 - 72 of 112
Design by Adaptive Theme